Comparing Vedolizumab, Ustekinumab, and JAK Inhibitors for Ulcerative Colitis After Anti-TNF Alpha Therapy
Led by Humanitas Clinical and Research Center · Updated on 2024-11-15
450
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-life effectiveness and safety of three different treatmentsvedolizumab, ustekinumab, and JAK inhibitorsin patients with ulcerative colitis UC who have previously been treated with at least one anti-TNF-alpha therapy. This observational study aims to compare these therapies over a period of 12 months to better understand how they perform in routine clinical settings.
The study includes patients who are starting one of the three treatments as a second-line target therapy after anti-TNF-alpha failure or intolerance. The treatments being observed are vedolizumab, ustekinumab at standard dosage, and JAK inhibitors such as tofacitinib, upadacitinib, or filgotinib. Participants receive their prescribed treatments as part of their usual medical care the study monitors their progress and outcomes without altering treatment.
Participants will be followed for at least one visit after starting the treatment to assess clinical and endoscopic effectiveness over 12 months. Researchers will collect data on how well each treatment controls disease activity and safety profiles. The study involves regular clinical assessments according to routine practice to evaluate participants health status and treatment responses during this period.
CONDITIONS
Brief Title
The PODIUM Study - a Three-arm Comparison of Target Therapies After Anti-TNFα in Ulcerative Colitis
Research Team
A
Alessandro Armuzzi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Established diagnosis of ulcerative colitis according to current European Crohn's and Colitis Organization guidelines
Age 18 years or older
Able to provide informed consent
Clinically active ulcerative colitis at baseline
Starting vedolizumab, ustekinumab, or JAK inhibitors as second-line therapy at baseline
Previous treatment with at least one anti-TNF-alpha drug for ulcerative colitis
No previous exposure to vedolizumab, ustekinumab, or JAK inhibitors before baseline
At least one follow-up visit after baseline
You will not qualify if you...
Diagnosis of Crohn's colitis, IBD-U, or other gastrointestinal inflammatory conditions
Age under 18 years
Unable to provide informed consent
Acute severe ulcerative colitis requiring hospitalization at baseline
No prior exposure to anti-TNF-alpha therapies
Previous treatment with target therapies other than anti-TNF-alpha for ulcerative colitis before baseline
Ustekinumab or JAK inhibitors induction with non-standard dosing for ulcerative colitis
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 12 months
Participants receive one of three drug therapies: vedolizumab, ustekinumab, or JAK inhibitors as second-line treatment for ulcerative colitis after anti-TNF-alpha failure or intolerance.
At least 1 follow-up visit after baseline
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of BDHK-2009 Tablets in Healthy Adults Aged 18 to 55
Study of Daily Pomegranate Juice Effects on Gut Inflammation, Quality of Life, and Gut Microbiome in Adults with Mild-to-Moderate Ulcerative Colitis
Study of Etrasimod Oral Treatment in Patients 65 and Older With Active Ulcerative Colitis
Real-World Evaluation of Guselkumab for Moderate-to-Severe Ulcerative Colitis Safety and Effectiveness
Effects of Mediterranean Diet Alone or with Time-Restricted Feeding on Gut Health and Quality of Life in Adults with Ulcerative Colitis in Remission
Effects of Partial Enteral Nutrition With LH VIOLA on Weight Loss and Muscle Loss in Adults With Inflammatory Bowel Disease at Nutritional Risk
Evaluating Safety and Effectiveness of ButyMixx Supplement for Adults with Ulcerative Colitis in Remission
Investigation of Intestinal Tissue Repair Mechanisms Using Organoid Technology in Inflammatory Bowel Disease Patients and Controls
Comparing Vedolizumab, Ustekinumab, and JAK Inhibitors for Ulcerative Colitis After Anti-TNF Alpha Therapy
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.
Giuseppe Privitera, Cristina Bezzio, Gisella Figlioli...